Skip to content

Assessment of Early GFR, Tubular Function and Pathology Changes Early and Late After Renal denervatioN

Assessment of Early GFR, Tubular Function and Pathology Changes Early and Late After Renal denervatioN

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07786636
Acronym
AEGEAN
Enrollment
50
Registered
2026-08-26
Start date
2026-09-01
Completion date
2028-08-01
Last updated
2026-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Denervation Therapy

Brief summary

The purpose of this clinical study is to better understand how renal denervation (RDN) affects kidney function, both shortly after and up to a year after the procedure. Renal denervation is a minimally invasive treatment used for patients with high blood pressure that does not respond well to medication ("resistant hypertension"). It works by reducing the activity of nerves that run along the arteries supplying the kidneys, which helps lower blood pressure. To understand how RDN affects the kidneys, we will measure kidney function in detail and analyse blood and urine samples collected before and after the procedure. This will help researchers see whether the procedure causes changes in the kidneys, and whether some of these changes are linked to better kidney health over time.

Interventions

DIAGNOSTIC_TESTblood sampling

Blood samples will be taken to examine the mGFR as parameter for kidney function

Sponsors

Rede Optimus Hospitalar SA
Lead SponsorNETWORK

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥18 years * eGFR \>30 ml/min/1.73m2 (CKD stages 3b and less severe) * Informed consent for study participation provided by the patient or the legal guardian * Patient information and consent to the processing of personal data * Stable therapy in the previous three months * All patients undergoing RDN for clinical indications

Exclusion criteria

* Patients in emergency situations * Turbid urine sample on admission * Visible haematuria in the urine sample on admission * Pregnancy * Allergy to contrast media (visipaque, omnipaque, iohexol) * Any problem, which, in the investigator's opinion, might jeopardize the participant's compliance with the protocol.

Design outcomes

Primary

MeasureTime frameDescription
Change of a specific protein score in urine between Baseline visit (Day 1) and 12 months follow-up visitBaseline visit (Day 1) and 12 months follow-up visitChange of a specific protein score in urine prior to standard of care index procedure and 12 months from index procedure. Samples will be stored until the last patient had the last visit. All measurements will be then done afterwards.

Contacts

CONTACTAlexandra Greindl, Dr
alexandra.greindl@redeoptimus.com+49 157 851 281 40

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 27, 2026